Legal Representation
Attorney
Andrea K. Shannon
USPTO Deadlines
Next Deadline
82 days remaining
Statement of Use Due - Extension 1 Granted
Due Date
October 22, 2025
Extension Available
Until October 22, 2025
Application History
14 eventsDate | Code | Type | Description | Documents |
---|---|---|---|---|
Apr 22, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
Apr 22, 2025 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
Apr 21, 2025 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
Apr 21, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
Dec 25, 2024 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | Loading... |
Oct 22, 2024 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
Aug 27, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
Aug 27, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
Aug 7, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
Jul 24, 2024 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
Jul 23, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
Apr 9, 2024 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
Apr 9, 2024 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
Dec 22, 2023 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for use in the treatment of diseases and disorders in the cardiovascular, vascular and hematology fields, made in significant part of bucindolol hcl
Additional Information
Design Mark
The mark consists of two intertwined curved lines inside of a stylized image of a heart with the words "GENCARO BUCINDOLOL HCL" to the right. "GENCARO" is in bold font. Underneath is "BUCINDOLOL HCL".
Color Claim
Color is not claimed as a feature of the mark.
Classification
International Classes
005
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"BUCINDOLOL HCL"